《慢性阻塞性肺疾病全球创议》2025更新评论:聚焦个体化治疗、并发症管理及疫苗接种

doi:10.19983/j.issn.2096-8493.2024161

结核与肺部疾病杂志 ›› 2025, Vol. 6 ›› Issue (2): 125-127.doi: 10.19983/j.issn.2096-8493.2024161

《慢性阻塞性肺疾病全球创议》2025更新评论:聚焦个体化治疗、并发症管理及疫苗接种

蒋琦, 马义铭, 陈燕()

中南大学湘雅二医院呼吸与危重症医学科,长沙 410011

收稿日期:2024-11-18 出版日期:2025-04-20 发布日期:2025-04-11
通信作者: 陈燕,Email:chenyan99727@csu.edu.cn
基金资助:
国家自然科学基金(82370054);国家自然科学基金(82070049)

Review of the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) updates: focusing on personalized treatment, comorbidity management, and vaccination

Jiang Qi, Ma Yiming, Chen Yan()

Department of Respiratory and Critical Care Medicine, The Second Xiangya Hospital, Central South University, Changsha 410011, China

Received:2024-11-18 Online:2025-04-20 Published:2025-04-11
Contact: Chen Yan,Email:chenyan99727@csu.edu.cn
Supported by:
National Natural Science Foundation of China(82370054);National Natural Science Foundation of China(82070049)

摘要/Abstract

摘要：

慢性阻塞性肺疾病(简称“慢阻肺病”)是一种常见的、可预防和治疗的慢性气道疾病,特征为持续性气流受限和呼吸系统症状。由于慢阻肺病显著的异质性,精准的个体化治疗显得尤为重要。《慢性阻塞性肺疾病全球创议》2025(简称“GOLD 2025”) 的更新,通过整合最新循证医学成果,为慢阻肺病的管理带来了重要里程碑。作者重点对GOLD 2025中个体化治疗、并发症管理及疫苗接种进行评述,旨在为临床慢阻肺病工作者优化治疗和预防策略提供一定的参考及启示,以期提升患者生活质量并改善长期预后。

关键词: 肺疾病,慢性阻塞性, 治疗, 疾病管理, 评论

Abstract:

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable chronic airway disease characterized by persistent airflow limitation and respiratory symptoms. Given its significant heterogeneity, precise individualized treatment is of paramount importance. The 2025 update of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) represents a major milestone in COPD management by integrating the latest evidence-based findings and refining therapeutic strategies. The authors focuse on key updates in GOLD 2025, including personalized treatment, comorbidity management, and vaccination strategies. It aims to provide clinical COPD practitioners with insights and guidance to optimize treatment and prevention strategies, ultimately improving patients’ quality of life and long-term outcomes.

Key words: Pulmonary disease, chronic obstructive, Treatment, Disease management, Review

中图分类号:

R563.9

蒋琦, 马义铭, 陈燕. 《慢性阻塞性肺疾病全球创议》2025更新评论:聚焦个体化治疗、并发症管理及疫苗接种[J]. 结核与肺部疾病杂志, 2025, 6(2): 125-127. doi: 10.19983/j.issn.2096-8493.2024161

Jiang Qi, Ma Yiming, Chen Yan. Review of the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) updates: focusing on personalized treatment, comorbidity management, and vaccination[J]. Journal of Tuberculosis and Lung Disease, 2025, 6(2): 125-127. doi: 10.19983/j.issn.2096-8493.2024161

参考文献 21

[1]	Celli B, Fabbri L, Criner G, et al. Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision. Am J Respir Crit Care Med, 2022, 206(11):1317-1325. doi:10.1164/rccm.202204-0671PP.
[2]	Agustí A, Melén E, DeMeo DL, et al. Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene-environment interactions across the lifespan. Lancet Respir Med, 2022, 10(5):512-524. doi:10.1016/S2213-2600(21)00555-5. pmid: 35427533
[3]	Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther, 2010, 23(4):257-267. doi:10.1016/j.pupt.2010.03.003. pmid: 20381630
[4]	Ray R, Tombs L, Naya I, et al. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials. Pulm Pharmacol Ther. 2019,57:101802. doi:10.1016/j.pupt.2019.101802.
[5]	Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis, 2015, 10:2207-2217. doi:10.2147/COPD.S91694..
[6]	Chalmers JD, Laska IF, Franssen FME, et al. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. Eur Respir J, 2020, 55(6):1900790. doi:10.1183/13993003.00351-2020.
[7]	Singh D, Lea S, Mathioudakis AG. Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease. Drugs, 2021, 81(16):1821-1830. doi:10.1007/s40265-021-01616-9. pmid: 34731461
[8]	Anzueto A, Barjaktarevic IZ, Siler TM, et al. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase Ⅲ Trials (the ENHANCE Trials). Am J Respir Crit Care Med, 2023, 208(4):406-416. doi:10.1164/rccm.202306-0944OC.
[9]	Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med, 2024, 390(24):2274-2283. doi:10.1056/NEJMoa2401304.
[10]	Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: Role of comorbidities. Eur Respir J, 2006, 28(6):1245-1257. doi:10.1183/09031936.00133805. pmid: 17138679
[11]	Fabbri LM, Celli BR, Agustí A, et al. COPD and multimorbidity: recognising and addressing a syndemic occurrence. Lancet Respir Med, 2023, 11(11):1020-1034. doi:10.1016/S2213-2600(23)00261-8. pmid: 37696283
[12]	Hurst JR, Gale CP. MACE in COPD: addressing cardiopulmonary risk. Lancet Respir Med, 2024, 12(5):345-348. doi:10.1016/S2213-2600(24)00038-9.
[13]	Graul EL, Nordon C, Rhodes K, et al. Temporal Risk of Nonfatal Cardiovascular Events After Chronic Obstructive Pulmonary Disease Exacerbation: A Population-based Study. Am J Respir Crit Care Med, 2024, 209(8):960-972. doi:10.1164/rccm.202307-1122OC.
[14]	Kunisaki KM, Dransfield MT, Anderson JA, et al. Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. Am J Respir Crit Care Med, 2018, 198(1):51-57. doi:10.1164/rccm.201711-2239OC.
[15]	Kovacs G, Agusti A, Barberà JA, et al. Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?. Am J Respir Crit Care Med, 2018, 198(8):1000-1011. doi:10.1164/rccm.201801-0095PP.
[16]	Kovacs G, Avian A, Bachmaier G, et al. Severe Pulmonary Hypertension in COPD: Impact on Survival and Diagnostic Approach. Chest, 2022, 162(1):202-212. doi:10.1016/j.chest.2022.01.031. pmid: 35092746
[17]	Kobayashi M, Leidner AJ, Gierke R, et al. Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices-United States, 2024. MMWR Morb Mortal Wkly Rep,2024, 73(36):793-798. doi:10.15585/mmwr.mm7336a3.
[18]	Huang CL, Nguyen PA, Kuo PL, et al. Influenza vaccination and reduction in risk of ischemic heart disease among chronic obstructive pulmonary elderly. Comput Methods Programs Biomed, 2013, 111(2):507-511. doi:10.1016/j.cmpb.2013.05.006.
[19]	Wiseman DJ, Thwaites RS, Ritchie AI, et al. Respiratory Syncytial Virus-related Community Chronic Obstructive Pulmonary Disease Exacerbations and Novel Diagnostics: A Binational Prospective Cohort Study. Am J Respir Crit Care Med, 2024, 210(8):994-1001. doi:10.1164/rccm.202308-1320OC.
[20]	Melgar M, Britton A, Roper LE, et al. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices-United States, 2023. MMWR Morb Mortal Wkly Rep,2023, 72(29):793-801. doi:10.15585/mmwr.mm7229a4.
[21]	Hause AM, Moro PL, Baggs J, et al. Early Safety Findings Among Persons Aged ≥60 Years Who Received a Respiratory Syncytial Virus Vaccine-United States, May 3, 2023-April 14, 2024. MMWR Morb Mortal Wkly Rep, 2024, 73(21):489-494. doi:10.15585/mmwr.mm7321a3.

《慢性阻塞性肺疾病全球创议》2025更新评论:聚焦个体化治疗、并发症管理及疫苗接种

Review of the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) updates: focusing on personalized treatment, comorbidity management, and vaccination

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 21

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

[1]	陈华, 陈品儒. 《T/CHATA-001-2025非结核分枝杆菌病诊断》团体标准2025年更新版解读[J]. 结核与肺部疾病杂志, 2025, 6(2): 135-142.
[2]	中国人民解放军总医院第八医学中心结核病医学部, 《中国防痨杂志》编辑委员会, 《中国医疗保健国际交流促进会结核病学分会基础和临床学部. 结核性腹膜炎多学科诊疗专家共识[J]. 结核与肺部疾病杂志, 2025, 6(2): 143-157.
[3]	玉明柳, 龚贝贝, 陈跃华, 蓝伟恩, 韦海明, 甘霖, 陈向斓. 肺结核有创机械通气患者肺康复联合早期活动方案的效果分析[J]. 结核与肺部疾病杂志, 2025, 6(2): 217-224.
[4]	阎庆虎, 薛峰, 于泳, 秦毅, 阎庆梅, 崔嘉. 超声引导下微波消融技术在局限性结核病变治疗中的价值分析[J]. 结核与肺部疾病杂志, 2025, 6(1): 55-60.
[5]	张莹, 郭春辉. 结核性气管支气管狭窄的治疗研究进展[J]. 结核与肺部疾病杂志, 2025, 6(1): 87-93.
[6]	厉银锋, 叶雅利, 杨禧龙, 张海啸. 电针治疗对长期过量使用唑吡坦引起呼吸抑制的干预策略[J]. 结核与肺部疾病杂志, 2024, 5(S): 52-55.
[7]	夏莎莎. 急诊护理干预在慢性阻塞性肺疾病患者中的急诊治疗效果[J]. 结核与肺部疾病杂志, 2024, 5(S): 108-110.
[8]	彭莉. 慢性肾衰竭合并肺部感染患者治疗进展[J]. 结核与肺部疾病杂志, 2024, 5(S): 165-168.
[9]	马晓玲, 赵永年, 段丽丽, 刘新文. 新疆生产建设兵团2016—2022年肺结核患者不良转归列线图预测模型的构建与验证[J]. 结核与肺部疾病杂志, 2024, 5(6): 552-559.
[10]	孙慧娟, 苏伟, 陈伟. 利福平耐药结核病患者不良治疗结局及其影响因素研究进展[J]. 结核与肺部疾病杂志, 2024, 5(6): 573-582.
[11]	云南省传染性疾病临床医学中心, 云南省医院协会呼吸内科专业委员会, 昆明市医学会肺结节早诊早治专业委员会. 肺结节规范化诊治专家共识[J]. 结核与肺部疾病杂志, 2024, 5(5): 388-397.
[12]	袁丽荣, 杨青龙, 李育玲, 李琳, 邓莎莎, 李淑花. 计算机化认知行为疗法在慢性阻塞性肺疾病患者症状群管理中的影响:一项随机对照试验[J]. 结核与肺部疾病杂志, 2024, 5(5): 476-483.
[13]	仵倩红, 张燕, 刘鑫. 多学科持续发力终结结核病流行[J]. 结核与肺部疾病杂志, 2024, 5(4): 279-282.
[14]	李亚波, 樊丽娟, 孙秀利, 缑良芝, 任倍莹, 师娟子, 王芳, 马晓玲, 谢永宏, 刘鑫, 仵倩红. 女性不孕症在行体外受精-胚胎移植前结核感染筛查及诊疗进展[J]. 结核与肺部疾病杂志, 2024, 5(4): 352-357.
[15]	张悦, 朱晓筱, 顾芬. 慢性阻塞性肺疾病患者综合护理管理的机遇与挑战[J]. 结核与肺部疾病杂志, 2024, 5(3): 187-190.